

論文全著者名. 論題. 雑誌名. 発行年; 巻 :始頁-終頁	雑誌名
Masakazu Toi , Shigeru Imoto , Takanori Ishida , Yoshinori Ito , Hiroji Iwata , Norikazu Masuda , Hirofumi Mukai , Shigehira Saji , Akira Shimizu , Takafumi Ikeda , Hironori Haga , Toshiaki Saeki , Kenjiro Aogi , Tomoharu Sugie , Takayuki Ueno , Takayuki Kinoshita , Yuichiro Kai , Masahiro Kitada , Yasuyuki Sato , Kenjiro Jimbo , Nobuaki Sato , Hiroshi Ishiguro , Masahiro Takada , Yasuo Ohashi , Shinji Ohno .Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial.2021 Jan;22(1):74-84.	Lancet Oncol.
Akezaki Y, Nakata E, Kikuuchi M , Tominaga R, Kurokawa H, Hamada M, Aogi K, Ohsumi S, Sugihara S.Influence of and Risk Factors for Axillary Web Syndrome Following Surgery for Breast Cancer. 2021 Feb;75(1):39-44.	Acta Med Okayama.
Ono S, Kawada K, Dohi O, Kitamura S, Koike T, Hori S , Kanzaki H, Murao T, Yagi N, Sasaki F, Hashiguchi K, Oka S, Katada K, Shimoda R, Mizukami K, Suehiro M, Takeuchi T, Katsuki S, Tsuda M, Naito Y, Kawano T, Haruma K, Ishikawa H, Mori K, Kato Md M.Linked Color Imaging Focused on Neoplasm Detection in the Upper Gastrointestinal Tract : A Randomized Trial .2021 Jan;174(1):18-24	Ann Intern Med.
Shimizu K, Ohtaki Y, Suzuki K, Date H, Yamashita M , Iizasa T, Ito H, Yoshimura K, Okada M, Chida M; Japanese Association for Chest Surgery.Salvage surgery for non-small-cell lung cancer after definitive radiotherapy.2020 Nov 26;S0003-4975(20)32021-X. doi: 10.1016/j.athoracsur.2020.10.035. Online ahead of print.	Ann Thorac Surg.
Zhang X, Yamamoto Y, Wang X, Sato M, Imanishi M, Sugaya A, Hirose M, Endo S, Moriwaki T, Yamato K, Hyodo I .MDM4 as a Prognostic Factor for Patients With Gastric Cancer With Low Expression of p53.2021 Mar;41(3):1475-1483.	Anticancer Res.
Ohmachi K, Kinoshita T, Tobinai K, Ogawa G, Mizutani T, Yamauchi N, Fukuhara N, Uchida T, Yamamoto K, Miyazaki K, Tsukamoto N, Iida S, Utsumi T, Yoshida I , Imaizumi Y, Tokunaga T, Yoshida S, Masaki Y, Murayama T, Yakushijin Y, Suehiro Y, Nosaka K, Dobashi N, Kuroda J, Takamatsu Y, Maruyama D, Ando K, Ishizawa K, Ogura M, Yoshino T, Hotta T, Tsukasaki K, Nagai H; Japan Clinical Oncology Group.A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial.2021 Feb 23;5(4):984-993.	Blood Adv.
Miyake M, Iida K, Nishimura N, Miyamoto T, Fujimoto K, Tomida R , Matsumoto K, Numakura K, Inokuchi J, Morizane S, Yoneyama T, Matsumura Y, Abe T, Inoue M, Yamada T, Terada N, Hirao S, Uemura M, Matsushita Y, Taoka R, Kobayashi T, Kojima T, Matsui Y, Kitamura H, Nishiyama H; Japanese Urological Oncology Group.Non-maintenance intravesical Bacillus Calmette-Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study.2021 Mar 11;21(1):266.	BMC Cancer
Imaoka H, Ikeda M, Maehara K, Umemoto K, Ozaka M, Kobayashi S, Terashima T, Inoue H, Sakaguchi C , Tsuji K, Shioji K, Okamura K, Kawamoto Y, Suzuki R, Shirakawa H, Nagano H, Ueno M, Morizane C, Furuse J.Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort study .2020 Oct 1;20(1):946.	BMC Cancer.
Furukawa S, Yagi S, Shiraishi K, Mori K, Ninomiya T, Kawasaki K, Mizukami Y, Suzuki S, Uraoka M, Shibata N, Nakamura S, Imamine S, Murakami H, Ohashi K, Torisu M, Hasebe A , Yano H, Murakami M, Takeshita E, Ikeda Y, Hiasa Y.Association between platelet count and mucosal healing in Japanese patients with ulcerative colitis: a cross-sectional study.2020 Nov 16;20(1):384.	BMC Gastroenterol.
Matsui R, Suzuki K, Takiguchi T, Nishio M, Koike T, Hayashi T, Seto T, Kogure Y, Nogami N , Fujiwara K, Kaneda H, Harada T, Shimizu S, Kimura M, Kenmotsu H, Shimokawa M, Goto K.5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study.2020 Oct 6;21(1):72.	BMC Pharmacol Toxicol.
Creelan BC, Yeh TC, Kim SW, Nogami N , Kim DW, Chow LQM, Kanda S, Taylor R, Tang W, Tang M, Angell HK, Roudier MP, Marotti M, Gibbons DLA Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naïve patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer.2021 Jan;124(2):383-390	Br J Cancer.
Mukai H, Yamaguchi T, Takahashi M, Hozumi Y, Fujisawa T, Ohsumi S , Akabane H, Nishimura R, Takashima T, Park Y, Sagara Y, Toyama T, Imoto S, Mizuno T, Yamashita S, Fujii S, Uemura Y.Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study.2020 Jun;122(12):1747-1753	Br J Cancer.
Ogiya R, Niikura N, Kumamaru H, Takeuchi Y, Okamura T, Kinoshita T, Aogi K , Anan K, Iijima K, Ishida T, Iwamoto T, Kawai M, Kojima Y, Sakatani T, Sagara Y, Hayashi N, Masuoka H, Yoshida M, Miyata H, Tsuda H, Imoto S, Jinno H.Breast cancer survival among Japanese individuals and US residents of Japanese and other origins: a comparative registry-based study.2020 Nov;184(2):585-596.	Breast Cancer Res Treat.

Ohno S, Saji S, Masuda N, Tsuda H, Akiyama F, Kurosumi M, Shimomura A, Sato N, Takao S, Ohsumi S , Tokuda Y, Inaji H, Watanabe T, Ohashi Y. Relationships between pathological factors and long-term outcomes in patients enrolled in two prospective randomized controlled trials comparing the efficacy of oral tegafur-uracil with CMF (N-SAS-BC 01 trial and CUBC trial). 2021 Feb;186(1):135-147.	Breast Cancer Res Treat.
Takahashi M, Ohtani S, Nagai SE, Takashima S , Yamaguchi M, Tsuneizumi M, Komoike Y, Osako T, Ito Y, Ikeda M, Ishida K, Nakayama T, Takashima T, Asakawa T, Matsumoto S, Shimizu D, Masuda N. The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study. 2021 Jan;185(1):125-134	Breast Cancer Res Treat.
O'Shaughnessy J, Brezden-Masley C, Cazzaniga M, Dalvi T, Walker G, Bennett J, Ohsumi S . Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study. 2020 Oct 27;22(1):114.	Breast Cancer Res.
Hayashi N, Kumamaru H, Isozumi U, Aogi K , Asaga S, Iijima K, Kadoya T, Kojima Y, Kubo M, Miyashita M, Miyata H, Nagahashi M, Niikura N, Ogo E, Tamura K, Tanakura K, Yamamoto Y, Yoshida M, Imoto S, Jinno H. Annual report of the Japanese Breast Cancer Registry for 2017. 2020 Sep;27(5):803-809.	Breast Cancer.
Kubo M, Kumamaru H, Isozumi U, Miyashita M, Nagahashi M, Kadoya T, Kojima Y, Aogi K , Hayashi N, Tamura K, Asaga S, Niikura N, Ogo E, Iijima K, Tanakura K, Yoshida M, Miyata H, Yamamoto Y, Imoto S, Jinno H. Annual Report of the Japanese Breast Cancer Society Registry for 2016. 2020 Jul;27(4):511-518.	Breast Cancer.
Kawaguchi H, Masuda N, Nakayama T, Aogi K , Anan K, Ito Y, Ohtani S, Sato N, Saji S, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H, Yamashita T, Yamamoto Y, Yotsumoto D, Toi M, Ohno S. Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-Co6 Safari study. 2020 May;27(3):389-398.	Breast Cancer.
Kotaka M, Saito Y, Kato T, Satake H, Makiyama A, Tsuji Y, Shinozaki K, Fujiwara T, Mizushima T, Harihara Y, Nagata N, Kurihara N, Ando M, Kusakawa G, Sakai T, Uchida Y, Takamoto M, Kimoto S, Hyodo I . A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy. 2020 Nov;86(5):607-618.	Cancer Chemother Pharmacol.
Ichihara E, Harada D , Inoue K, Shibayama T, Hosokawa S, Kishino D, Harita S, Ochi N, Oda N, Hara N, Hotta K, Maeda Y, Kiura K. Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors. 2021 Jan;70(1):101-106.	Cancer Immunol Immunother.
Ueno M, Morizane C, Furukawa M, Sakai D, Komatsu Y, Nakai Y, Tsuda M, Ozaka M, Mizuno N, Muto M, Fukutomi A, Ikeda M, Tsuji A, Katanuma A, Moriwaki T, Kajiwara T , Ishii H, Negoro Y, Shimizu S, Nemoto N, Kobayashi S, Makino K, Furuse J. A randomized, double-blind, phase II study of oral histone deacetylase inhibitor resminostat plus S-1 versus placebo plus S-1 in biliary tract cancers previously treated with gemcitabine plus platinum-based chemotherapy. 2021 Mar;10(6):2088-2099	Cancer Med.
Shimokawa T, Yamada K, Tanaka H, Kubota K, Takiguchi Y, Kishi K, Saito H, Hosomi Y, Kato T, Harada D , Otani S, Kasai T, Nakamura Y, Misumi T, Yamanaka T, Okamoto H. Randomized phase II trial of S-1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer. 2021 Jan;10(2):626-633.	Cancer Med.
Horinouchi H, Atagi S, Oizumi S, Ohashi K, Kato T, Kozuki T , Seike M, Sone T, Sobue T, Tokito T, Harada H, Maeda T, Mio T, Shirosaka I, Hattori K, Shin E, Murakami H. Real-world outcomes of chemoradiotherapy for unresectable Stage III non-small cell lung cancer: The SOLUTION study. 2020 Sep;9(18):6597-6608.	Cancer Med.
Matsumoto K, Takahashi M, Sato K, Osaki A, Takano T, Naito Y, Matsuura K, Aogi K , Fujiwara K, Tamura K, Baba M, Tokunaga S, Hirano G, Imoto S, Miyazaki C, Yanagihara K, Imamura CK, Chiba Y, Saeki T. A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide. 2020 May;9(10):3319-3327.	Cancer Med.
Tamiya A, Koh Y, Isa SI, Kubo A, Ando M, Saka H, Yoshimoto N, Takeo S, Adachi H, Tagawa T, Kawashima O, Yamashita M , Kataoka K, Takenoyama M, Takeuchi Y, Watanabe K, Matsumura A, Kawaguchi T. Impact of somatic mutations on prognosis in resected non-small-cell lung cancer: The Japan Molecular Epidemiology for lung cancer study. 2020 Apr;9(7):2343-2351.	Cancer Med.
Hasegawa H, Taniguchi H, Nakamura Y, Kato T, Fujii S, Ebi H, Shiozawa M, Yuki S, Masuishi T, Kato K, Izawa N, Moriwaki T, Oki E, Kagawa Y, Denda T, Nishina T , Tsuji A, Hara H, Esaki T, Nishida T, Kawakami H, Sakamoto Y, Miki I, Okamoto W, Yamazaki K, Yoshino T. FMS-like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer. 2021 Jan;112(1):314-322	Cancer Sci.

Onuki M, Matsumoto K, Iwata T, Yamamoto K, Aoki Y, Maenohara S, Tsuda N, Kamiura S, Takehara K , Horie K, Tasaka N, Yahata H, Takei Y, Aoki Y, Kato H, Motohara T, Nakamura K, Ishikawa M, Kato T, Yoshida H, Matsumura N, Nakai H, Shigeta S, Takahashi F, Noda K, Yaegashi N, Yoshikawa H. Human Papillomavirus Genotype Contribution to Cervical Cancer and Precancer: Implications for Screening and Vaccination in Japan. 2020 Jul;111(7):2546-2557.	Cancer Sci.
Osawa T, Kojima T, Hara T, Sugimoto M, Eto M, Takeuchi A, Minami K, Nakai Y, Ueda K, Ozawa M, Uemura M, Miyauchi Y, Ohba K, Suzuki T, Anai S, Shindo T, Kusakabe N, Tamura K, Komiyama M, Goto T, Yokomizo A, Kohei N, Kashiwagi A, Murakami M, Sazuka T, Yasumoto H, Iwamoto H, Mitsuzuka K, Morooka D, Shimazui T, Yamamoto Y, Ikeshiro S, Nakagomi H, Morita K, Tomida R , Mochizuki T, Inoue T, Kitamura H, Yamada S, Ito YM, Murai S, Nishiyama H, Shinohara N; Japanese Urological Oncology Group. Oncological Outcomes of a Multicenter Cohort Treated With Axitinib for Metastatic Renal Cell Carcinoma. 2020 Jul;111(7):2460-2471.	Cancer Sci.
Sakai K, Tsuboi M, Kenmotsu H, Yamanaka T, Takahashi T, Goto K, Daga H, Ohira T, Ueno T , Aoki T, Nakagawa K, Yamazaki K, Hosomi Y, Kawaguchi K, Okumura N, Takiguchi Y, Sekine A, Haruki T, Yamamoto H, Sato Y, Akamatsu H, Seto T, Saeki S, Sugio K, Nishio M, Okabe K, Yamamoto N, Nishio K. Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANG-TR). 2021 Jan;112(1):388-396.	Cancer Sci.
Seto T, Hayashi H, Satouchi M, Goto Y, Niho S, Nogami N , Hida T, Takahashi T, Sakakibara-Konishi J, Morise M, Nagasawa T, Suzuki M, Ohkura M, Fukuhara K, Thurm H, Peltz G, Nishio M. Lorlatinib in previously-treated ALK-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study. 2020 Oct;111(10):3726-3738.	Cancer Sci.
Nishio M, Kato T, Niho S, Yamamoto N, Takahashi T, Nogami N , Kaneda H, Fujita Y, Wilner K, Yoshida M, Isozaki M, Wada S, Tsuji F, Nakagawa K. Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer. 2020 May;111(5):1724-1738.	Cancer Sci.
Kano H, Ichihara E, Harada D , Inoue K, Kayatani H, Hosokawa S, Kishino D, Watanabe K, Ochi N, Oda N, Hara N, Ninomiya K, Hotta K, Maeda Y, Kiura K. Utility of immune checkpoint inhibitors in non-small-cell lung cancer patients with poor performance status. 2020 Oct;111(10):3739-3746.	Cancer Sci.
Ito K, Kobayashi M, Komiyama M, Naito S, Nishimura K, Yonese J, Hashine K , Saito S, Arai G, Shinohara M, Masumori N, Shimizu N, Satoh T, Yamauchi A, Tochigi T, Takezawa Y, Fujimoto H, Yokomizo A, Kakimoto KI, Fukui I, Karasawa K, Tsukamoto T, Nozaki M, Hasumi M, Ishiyama H, Ohtani M, Kuwahara M, Harada M, Ohashi Y, Kotake T, Kakizoe T, Suzuki K, Yamanaka H; National Research Project on Endocrine-Radiation Combination Therapy for Locally Advanced Prostate Cancer Investigators. Oncological outcomes for patients with locally advanced prostate cancer treated with neoadjuvant endocrine and external-beam radiation therapy followed by adjuvant continuous/intermittent endocrine therapy in an open-label, randomized, phase 3 trial. 2020 Sep 1;126(17):3961-3971.	Cancer.
Saito Y, Hayashi R, Iida Y, Mizumachi T, Fujii T, Matsumoto F, Beppu T, Yoshida M, Shinomiya H, Kamiyama R, Kitano M, Yokoshima K, Fujimoto Y, Hama T, Yamashita T, Okami K, Miura K, Fujisawa T, Sano D, Kato H, Minami S, Sugawara M, Masuda M, Ota I, Iwae S, Kawata R, Monden N , Imai T, Asakage T, Okada M, Yoshikawa T, Tanioka K, Kitayama M, Doi M, Fujii S, Fujii M, Oridate N, Nakamizo M, Yoshimoto S, Homma A, Nibu KI, Yane K. Optimization of therapeutic strategy for p16-positive oropharyngeal squamous cell carcinoma: Multi-institutional observational study based on the national head and neck cancer registry of Japan. 2020 Sep 15;126(18):4177-4187.	Cancer.
Takashima T, Hara F, Iwamoto T, Uemura Y, Ohsumi S , Yotsumoto D, Hozumi Y, Watanabe T, Saito T, Watanabe KI, Tsurutani J, Toyama T, Akabane H, Nishimura R, Taira N, Ohashi Y, Mukai H. A Correlation Analysis Between Metabolism-related Genes and Treatment Response to S-1 as First-line Chemotherapy for Metastatic Breast Cancer: The SELECT BC-EURECA Study. 2021 Feb 1;S1526-8209(21)00040-9. doi: 10.1016/j.clbc.2021.01.018. Online ahead of print.	Clin Breast Cancer.
Kawazoe A, Kuboki Y, Shinozaki E, Hara H, Nishina T , Komatsu Y, Yuki S, Wakabayashi M, Nomura S, Sato A, Kuwata T, Kawazu M, Mano H, Togashi Y, Nishikawa H, Yoshino T. Multicenter phase 1/2 Trial of napabucasin and pembrolizumab in patients with metastatic colorectal cancer (EPOC1503/SCOOP Trial). 2020 Nov 15;26(22):5887-5894.	Clin Cancer Res.
Nakajima TE, Kadowaki S, Minashi K, Nishina T , Yamanaka T, Hayashi Y, Izawa N, Muro K, Hironaka S, Kajiwara T, Kawakami Y. Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer. 2021 Feb 15;27(4):1029-1036.	Clin Cancer Res.
Kensei Yamaguchi, Yasuhiro Shimada, Shuichi Hironaka, Naotoshi Sugimoto, Yoshito Komatsu, Tomohiro Nishina , Yasushi Omuro, Takao Tamura, Yongzhe Piao, Gosuke Homma, Min-Hua Jen, Astra M Liepa, Kei Muro. Quality of Life Associated with Ramucirumab Treatment in Patients with Advanced Gastric Cancer in Japan: Exploratory Analysis from the Phase III RAINBOW Trial. 2021 Jan;41(1):53-64.	Clin Drug Investig

<p>Kana Shiraishi, Shinya Furukawa, Sen Yagi, Kenichirou Mori, Tomoyuki Ninomiya, Keitarou Kawasaki, Yuji Mizukami, Seiyuu Suzuki, Masayoshi Uraoka , Naozumi Shibata, Sanae Nakamura, Satoshi Imamine, Hidehiro Murakami, Katsuhisa Ohashi, Masamoto Torisu, Makoto Yano, <u>Aki Hasebe</u>, Harumi Yano , Masato Murakami, Eiji Takeshita , Yoshio Ikeda , Yoichi Hiasa. Serum Globulin Is Associated with Endoscopic Findings and Mucosal Healing in Japanese Patients with Ulcerative Colitis. 2021 Feb 4. doi: 10.1007/s10620-021-06834-5. Online ahead of print.</p>	<p>Dig Dis Sci.</p>
<p>Kishino T, Mori T, Miyashita T, Ouchi Y, Samukawa Y, Fukumura T, Takahashi S, <u>Monden N</u>, Akisada N, Hayashi Y, Nakamura M, Hoshikawa H. The Utility of Glasgow Prognostic Score and Palliative Prognostic Index in Patients With Head and Neck Squamous Cell Carcinoma Under Palliative Care. 2021 Mar 26;1455613211005114. doi: 10.1177/01455613211005114. Online ahead of print.</p>	<p>Ear Nose Throat J.</p>
<p>Satoshi Yamasaki, Akiko Kada, Ilseung Choi, Hiroatsu Iida, Naohiro Sekiguchi, Naoko Harada, Morio Sawamura, Takeshi Shimomura, Takuya Komeno, Takahiro Yano, <u>Isao Yoshida</u>, Shinichiro Yoshida, Kazutaka Sunami, Terutoshi Hishita, Hiroshi Takatsuki, Koichi Ohshima, Morishige Takeshita, Akiko M. Saito, Hiromi Iwasaki, Hirokazu Nagai. Phase II study of dose-adjusted gemcitabine, dexamethasone, cisplatin, and rituximab in elderly relapsed diffuse large B-cell lymphoma patients. 2020 Oct;1:507-516.</p>	<p>eJHaem</p>
<p>Okishio K, Morita R, Shimizu J, Saito H, Sakai H, Kim YH, Hataji O, Yomota M, Nishio M, Aoe K, Kanai O, Kumagai T, Kibata K, Tsukamoto H, Oizumi S, Fujimoto D, Tanaka H, Mizuno K, Masuda T, <u>Kozuki T</u>, Haku T, Suzuki H, Okamoto I, Hoshiyama H, Yada N, Ohe Y. Nivolumab treatment of elderly Japanese patients with non-small cell lung cancer: subanalysis of a real-world retrospective observational study (CA209-9CR). 2020 Jul;5(4):e000656.</p>	<p>ESMO Open.</p>
<p>Hironaka S, Komori A, Machida R, Ito Y, Takeuchi H, Ogawa G, Kato K, Onozawa M, Minashi K, Yano T, Nakamura K, Tsushima T, Hara H, <u>Nozaki I</u>, Ura T, Chin K, Fukuda H, Kitagawa Y. The association of primary tumor site with acute adverse event and efficacy of definitive chemoradiotherapy for cStage II/III esophageal cancer: an exploratory analysis of JCOG0909. 2020 Oct;17(4):417-424.</p>	<p>Esophagus.</p>
<p>Kentaro Ito, Takeharu Yamanaka, Hidetoshi Hayashi, Yoshihiro Hattori, Kazumi Nishino, Haruki Kobayashi, Yuko Oya, Toshihide Yokoyama, Takashi Seto, Koichi Azuma, Tomoya Fukui, <u>Toshiyuki Kozuki</u>, Atsushi Nakamura, Kentaro Tanaka, Katsuya Hirano, Takashi Yokoi, Haruko Daga, Shinya Sakata, Daichi Fujimoto, Masahide Mori, Ken Maeno, Takuya Aoki , Atsuhisa Tamura, Satoru Miura, Satoshi Watanabe, Hiroaki Akamatsu, Osamu Hataji, Kensuke Suzuki, Shigeto Hontsu, Koji Azuma , Akihiro Bessho, Akihito Kubo, Motoyasu Okuno, Kazuhiko Nakagawa, Nobuyuki Yamamoto . Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study. 2021 Mar;145:183-193.</p>	<p>Eur J Cancer.</p>
<p>Sakai D, Taniguchi H, Sugimoto N, Tamura T, <u>Nishina T</u>, Hara H, Esaki T, Denda T, Sakamoto T, Okuda H, Satoh T, Tsushima T, Makiyama A, Tsuda T, Hosokawa A, Kuramochi H, Tokunaga S, Moriwaki T, Yasui H, Ishida H, Tsuji A, Otsu S, Shimokawa H, Baba E, Sato M, Matsumoto S, Ozaki Y, Shinozaki K, Tamagawa H, Goto M, Kadowaki S, Fujii H, Koh Y, Yamazaki K, Hironaka S, Kishimoto J, Boku N, Hyodo I, Muro K. Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G). 2020 Aug;135:11-21. doi: 10.1016/j.ejca.2020.04.014. Epub 2020 Jun 8.</p>	<p>Eur J Cancer.</p>
<p>Kawazoe A, Yamaguchi K, Yasui H, Negoro Y, Azuma M, Amagai K, Hara H, Baba H, Tsuda M, Hosaka H, Kawakami H, Oshima T, Omuro Y, Machida N, Esaki T, Yoshida K, <u>Nishina T</u>, Komatsu Y, Han SR, Shiratori S, Shitara K. Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study. 2020 Apr;129:97-106.</p>	<p>Eur J Cancer.</p>
<p>Chida K, Kotani D, Moriwaki T, Fukuoka S, Masuishi T, Takashima A, Kumekawa Y, <u>Kajiwara T</u>, Yamazaki K, Komoda M, Makiyama A, Denda T, Hatachi Y, Suto T, Sugimoto N, Enomoto M, Ishikawa T, Kashiwada T, Ando K, Yuki S, Okita Y, Kusaba H, Sakai D, Okamoto K, Tamura T, Yamashita K, Goshio M, Shimada Y. Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS). 2021 Mar 8;11:576036.</p>	<p>Front Oncol.</p>
<p>Narita Y, Shoji H, Kawai S, Mizukami T, Nakamura M, Moriwaki T, Yamanaka T, Sunakawa Y, Kawakami H, <u>Nishina T</u>, Misumi T, Muro K. REVIVE study: a prospective observational study in chemotherapy after nivolumab therapy for advanced gastric cancer. 2021 Mar;17(8):869-875.</p>	<p>Future Oncol.</p>
<p><u>Hino K, Kajiwara T, Nishina T, Inoue T, Yoshimatsu M, Sakaguchi C, Nakasya A, Nishide N, Asagi A, Hasebe A, Terao T, Hori S, Nadano S, Hamamoto Y, Kataoka M, Tanimizu M</u>. Tolerability of Definitive Chemoradiotherapy in Elderly Patients with Esophageal Cancer. 2020 Nov;47(11):1577-1581.</p>	<p>Gan To Kagaku Ryoho.</p>

Takizawa K, Ono H, Hasuie N, Takashima A, Minashi K, Boku N, Kushima R, Katayama H, Ogawa G, Fukuda H, Fujisaki J, Oda I, Yano T, Hori S , Doyama H, Hirasawa K, Yamamoto Y, Ishihara R, Tanabe S, Niwa Y, Nakagawa M, Terashima M, Muto M; Gastrointestinal Endoscopy Group (GIESG) and the Stomach Cancer Study Group (SCSG) of Japan Clinical Oncology Group. A nonrandomized, single-arm confirmatory trial of expanded endoscopic submucosal dissection indication for undifferentiated early gastric cancer: Japan Clinical Oncology Group study (JCOG1009/1010). 2021 Mar;24(2):479-491	Gastric Cancer.
Iwasaki Y, Terashima M, Mizusawa J, Katayama H, Nakamura K, Katai H, Yoshikawa T, Ito S, Kaji M, Kimura Y, Hirao M, Yamada M, Kurita A , Takagi M, Lee SW, Takagane A, Yabusaki H, Hihara J, Boku N, Sano T, Sasako M. Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial. 2021 Mar;24(2):492-502.	Gastric Cancer.
Tokunaga M, Kurokawa Y, Machida R, Sato Y, Takiguchi S, Doki Y, Yabusaki H, Watanabe M, Hato S , Nakamori M, Ito S, Yoshikawa T, Terashima M. Impact of postoperative complications on survival outcomes in patients with gastric cancer: exploratory analysis of a randomized controlled JCOG1001 trial. 2021 Jan;24(1):214-223	Gastric Cancer.
Nakajima TE, Yamaguchi K, Boku N, Hyodo I, Mizusawa J, Hara H, Nishina T , Sakamoto T, Shitara K, Shinozaki K, Katayama H, Nakamura S, Muro K, Terashima M. Randomized phase II/III study of 5-fluorouracil/l-leucovorin versus 5-fluorouracil/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108/WJOG7312G). 2020 Jul;23(4):677-688.	Gastric Cancer.
Yoshida N, Doyama H, Yano T, Horimatsu T, Uedo N, Yamamoto Y, Kakushima N, Kanzaki H, Hori S , Yao K, Oda I, Katada C, Yokoi C, Ohata K, Yoshimura K, Ishikawa H, Muto M. Early Gastric Cancer Detection in High-Risk Patients: A Multicentre Randomised Controlled Trial on the Effect of Second-Generation Narrow Band Imaging. 2021 Jan;70(1):67-75	Gut.
Takehara K , Yamashita N, Watanabe R, Teramoto N, Tsuda H, Motohashi T, Harano K, Nakanishi T, Tokunaga H, Susumu N, Ueda Y, Yokoyama Y, Saito T. Clinical status and prognostic factors in Japanese patients with uterine leiomyosarcoma. 2020 Apr;157(1):115-120.	Gynecol Oncol.
Akezaki Y, Nakata E, Kikuuchi M , Tominaga R, Kurokawa H, Okamoto M, Hamada M, Aogi K, Ohsumi S, Sugihara S. Investigation of Factors Affecting Early Quality of Life of Patients after Breast Cancer Surgery. 2021 Feb 16;9(2):213.	Healthcare (Basel)
Yoshiteru Akezaki, Eiji Nakata, Ritsuko Tominaga , Ori Iwata, Juichi Kawakami, Tetsuya Tsuji, Tsuyoshi Ueno, Motohiro Yamashita, Shinsuke Sugihara. Short-Term Impact of Video-Assisted Thoracoscopic Surgery on Lung Function, Physical Function, and Quality of Life. 2021 Feb 1;9(2):136.	Healthcare (Basel)
Miura K, Tsujimura H, Masaki Y, Iino M, Takizawa J, Maeda Y, Yamamoto K, Tamura S, Yoshida A, Yagi H, Yoshida I , Kitazume K, Masunari T, Choi I, Kakinoki Y, Suzuki R, Yoshino T, Nakamura S, Hatta Y, Yoshida T, Kanno M. Consolidation with 90 Yttrium-ibritumomab tiuxetan after bendamustine and rituximab for relapsed follicular lymphoma. 2021 Feb;39(1):51-59	Hematol Oncol.
Tagashira H, Izushi Y, Ikuta T , Koike Y, Kitamura Y, Yamamoto H. Regimen of 5-Fluorouracil and Cisplatin Increases the Incidence of Extravasation in Patients Undergoing Chemotherapy. 2021 Mar-Apr;35(2):1147-1150	In Vivo.
Shinozaki K, Yamada T, Nasu J, Matsumoto T, Yuasa Y, Shiraiishi T, Nagano H, Moriyama I, Fujiwara T, Miguchi M, Yoshida R, Nozaka K, Tanioka H, Nagasaka T, Kurisu Y, Kobayashi M, Tsuchihashi K, Inukai M, Kikuchi T, Nishina T . A phase II study of FOLFOXIRI plus bevacizumab as initial chemotherapy for patients with untreated metastatic colorectal cancer: TRICC1414 (BeTRI). 2021 Feb;26(2):399-408	Int J Clin Oncol.
Hanai N, Shimizu Y, Kariya S, Yasumatsu R, Yokota T, Fujii T, Tsukahara K, Yoshida M, Hanyu K, Ueda T, Hirakawa H, Takahashi S, Ono T, Sano D, Yamauchi M, Watanabe A, Omori K, Yamazaki T, Monden N , Kudo N, Arai M, Sakurai D, Asakage T, Doi I, Yamada T, Homma A. Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice: a multicenter retrospective clinical. 2021 Mar;26(3):494-506.	Int J Clin Oncol.
Aogi K , Takeuchi H, Saeki T, Aiba K, Tamura K, Iino K, Imamura CK, Okita K, Kagami Y, Tanaka R, Nakagawa K, Fujii H, Boku N, Wada M, Akechi T, Iihara H, Ohtani S, Okuyama A, Ozawa K, Kim YI, Sasaki H, Shima Y, Takeda M, Nagasaki E, Nishidate T, Higashi T, Hirata K. Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis. 2021 Jan;26(1):1-17.	Int J Clin Oncol.
Moriwaki T, Fukuoka S, Masuishi T, Takashima A, Kumekawa Y, Kajiwara T , Yamazaki K, Esaki T, Makiyama A, Denda T, Hatachi Y, Suto T, Sugimoto N, Enomoto M, Ishikawa T, Kashiwada T, Oki E, Komatsu Y, Tsuji A, Tsuchihashi K, Sakai D, Ueno H, Tamura T, Yamashita K, Shimada Y. Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study. 2020 Apr;25(4):614-621.	Int J Clin Oncol.

Tohi Y, Kato T, Matsumoto R, Shinohara N, Shiga K, Yokomizo A, Nakamura M, Kume H, Mitsuzuka K, Sasaki H, Egawa S, Matsumura M, Hashine K , Inokuchi J, Eto M, Baba H, Ichikawa T, Kinoshita H, Matsuda T, Kakehi Y, Sugimoto M. The impact of complications after initial prostate biopsy on repeat protocol biopsy acceptance rate. Results from the Prostate Cancer Research International: Active Surveillance JAPAN study .2020 Dec;25(12):2107-2114.	Int J Clin Oncol.
Yamanaka S, Miyagawa M, Sugawara Y , Hasebe S, Fujii T, Takeuchi K, Tanaka K, Yakushijin Y. The prognostic significance of whole-body and spleen MTV (metabolic tumor volume) scanning for patients with diffuse large B cell lymphoma. 2021 Jan;26(1):225-232.	Int J Clin Oncol.
Okano N, Morizane C, Nomura S, Takahashi H, Tsumura H, Satake H, Mizuno N, Tsuji K, Shioji K, Asagi A , Yasui K, Kitagawa S, Kashiwada T, Ishiguro A, Kanai M, Ueno M, Ogura T, Shimizu S, Tobimatsu K, Motoya M, Nakashima K, Ikeda M, Okusaka T, Furuse J. Phase II Clinical Trial of Gemcitabine Plus Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma With a Family History of pancreatic/breast/ovarian/prostate Cancer or Personal History of breast/ovarian/prostate Cancer (FABRIC Study) .2020 Oct;25(10):1835-1843.	Int J Clin Oncol.
Nagao S, Yamamoto K, Oishi T, Yamaguchi S, Takehara K , Shimada M, Kigawa J. Phase II study of a new multidisciplinary therapy using once every 3 week carboplatin plus dose-dense weekly paclitaxel before and after radical hysterectomy for locally advanced cervical cancer. 2021 Jan;26(1):207-215.	Int J Clin Oncol.
Tomoya Yokota, Yosuke Ota, Hirofumi Fujii, Takeshi Kodaira, Mototsugu Shimokawa, Torahiko Nakashima, Nobuya Monden , Akihiro Homma, Shinya Ueda, Tetsuo Akimoto . Real-world clinical outcomes and prognostic factors in Japanese patients with recurrent or metastatic squamous cell carcinoma of head and neck treated with chemotherapy plus cetuximab: a prospective observation study (JROSG12-2). 2021 Feb;26(2):316-325.	Int J Clin Oncol.
Matsuda S, Suzuki R, Takahashi T, Suehiro Y, Tomita N, Izutsu K, Fukuhara N, Imaizumi Y, Shimada K, Nakazato T, Yoshida I , Miyazaki K, Yamaguchi M, Suzumiya J. Dose-adjusted EPOCH with or without rituximab for aggressive lymphoma patients: real world data .2020 Dec;112(6):807-816	Int J Hematol.
Inokuchi J, Kuroiwa K, Nishiyama H, Kojima T, Kakehi Y, Sugimoto M, Takenaka A, Fujimoto K, Yamaguchi R, Habuchi T, Hashine K , Mizusawa J, Eba J, Naito S. Significance of the timing of ureteral ligation on prognosis during radical nephroureterectomy for upper urinary tract urothelial cancer. 2021 Feb;28(2):208-214.	Int J Urol.
Nishijima TF, Toh Y, Tanimizu M , Nakagama H. Geriatric Screening for Hospitalized Older Adults with Cancer: A Survey of the Japanese Association of Clinical Cancer Centers. 2021 Mar 29. doi: 10.2169/internalmedicine.6760-20. Online ahead of print.	Intern Med
Hamada K, Kanzaki H, Inoue M, Ishiyama S, Yamauchi K, Miyahara K, Toyokawa T, Tsuzuki T, Miyaike J, Matsubara M, Takahashi S, Nishimura M, Takenaka R, Yunoki N, Hori S , Kobayashi S, Yamasaki Y, Kawahara Y, Ishikawa H, Okada H. Continued Aspirin Treatment May Be a Risk Factor of Delayed Bleeding after Gastric Endoscopic Submucosal Dissection under Heparin Replacement: A Retrospective Multicenter Study. 2020 Nov 1;59(21):2643-2651	Intern Med.
Nakahara Y, Shimokawa T, Misumi Y, Nogami N , Shinkai T, Seki N, Hosomi Y, Hida N, Okamoto H. Phase I/II study of erlotinib plus S-1 for patients with previously treated non-small cell lung cancer: Thoracic Oncology Research Group (TORG) 0808/0913. 2021 Feb;39(1):202-209.	Invest New Drugs.
Hara N, Ichihara E, Harada D , Inoue K, Fujiwara K, Hosokawa S, Kishino D, Haruyuki K, Ochi N, Oda N, Hotta K, Maeda Y, Kiura K. Significance of PD-L1 expression in the cytological samples of non-small cell lung cancer patients treated with immune checkpoint inhibitors. 2021 Mar 29. doi: 10.1007/s00432-021-03615-5. Online ahead of print.	J Cancer Res Clin Oncol.
Iwamuro M, Miyahara K, Sakaguchi C , Takenaka R, Kobayashi S, Mouri H, Tanaka S, Toyokawa T, Tanaka S, Nishimura M, Yamauchi K, Tanaka T, Okada H. Diagnostic Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Gastric Mesenchymal Tumors. 2020 May 1;9(5):1301.	J Clin Med.
Kenmotsu H, Yamamoto N, Yamanaka T, Yoshiya K, Takahashi T, Ueno T , Goto K, Daga H, Ikeda N, Sugio K, Seto T, Toyooka S, Date H, Mitsudomi T, Okamoto I, Yokoi K, Saka H, Okamoto H, Takiguchi Y, Tsuboi M. Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer. 2020 Jul 1;38(19):2187-2196.	J Clin Oncol.
Reck M, Wehler T, Orlandi F, Nogami N , Barone C, Moro-Sibilot D, Shtivelband M, González Larrriba JL, Rothenstein J, Früh M, Yu W, Deng Y, Coleman S, Shankar G, Patel H, Kelsch C, Lee A, Pialt E, Socinski MA. Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer. 2020 Aug 1;38(22):2530-2542.	J Clin Oncol.
Sunaga Y, Kurosawa M, Ochiai H, Watanabe H, Sueki H, Azukizawa H, Asada H, Watanabe Y, Yamaguchi Y, Aihara M, Mizukawa Y, Ohyama M, Hama N, Abe R, Hashizume H, Nakajima S, Nomura T, Kabashima K, Tohyama M , Takahashi H, Mieno H, Ueta M, Sotozono C, Niihara H, Morita E, Kokaze A. The nationwide epidemiological survey of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan, 2016-2018. 2020 Dec;100(3):175-182	J Dermatol Sci.

Mikiko Tohyama , Akira Matsumoto, Teruko Tsuda, Xiuju Dai, Ken Shiraishi, Koji Sayama. Suppression of IL-17A-induced CCL20 production by cytokine inducible SH2-containing protein 1 in epidermal keratinocytes. 2021 Mar;101(3):202-209.	J Dermatol Sci.
Tohyama M , Asagi A, Nakasya A, Iuchi S, Hashine K. Characteristic distribution of maculopapular rash caused by gemcitabine-based chemotherapy. 2021 Feb;48(2):215-218.	J Dermatol.
Yuta Maruki , Chigusa Morizane , Yasuhito Arai , Masafumi Ikeda , Makoto Ueno , Tatsuya Ioka , Atsushi Naganuma , Masayuki Furukawa , Nobumasa Mizuno , Tadashi Uwagawa , Naminatsu Takahara , Masashi Kanai , Akinori Asagi , Satoshi Shimizu , Atsushi Miyamoto , Seigo Yukisawa , Makoto Kadokura , Yasushi Kojima , Junji Furuse , Takako Eguchi Nakajima , Kentaro Sudo , Noritoshi Kobayashi , Natsuko Hama , Takeharu Yamanaka , Tatsuhiro Shibata , Takuji Okusaka . Correction to: Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study). 2021 Mar;56(3):297.	J Gastroenterol.
Maruki Y, Morizane C, Arai Y, Ikeda M, Ueno M, Ioka T, Naganuma A, Furukawa M, Mizuno N, Uwagawa T, Takahara N, Kanai M, Asagi A , Shimizu S, Miyamoto A, Yukisawa S, Kadokura M, Kojima Y, Furuse J, Nakajima TE, Sudo K, Kobayashi N, Hama N, Yamanaka T, Shibata T, Okusaka T. Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study) . 2021 Mar;56(3):250-260.	J Gastroenterol.
Kakushima N, Yoshida N, Doyama H, Yano T, Horimatsu T, Uedo N, Yamamoto Y, Kanzaki H, Hori S , Yao K, Oda I, Tanabe S, Yokoi C, Ohata K, Yoshimura K, Ishikawa H, Muto M. Near-focus magnification and second-generation narrow-band imaging for early gastric cancer in a randomized trial. 2020 Dec;55(12):1127-1137.	J Gastroenterol.
Okamoto A, Kondo E, Nakamura T, Yanagida S, Hamanishi J, Harano K, Hasegawa K, Hirasawa T, Hori K, Komiyama S, Matsuura M, Nakai H, Nakamura H, Sakata J, Tabata T, Takehara K , Takekuma M, Yokoyama Y, Kase Y, Sumino S, Soeda J, Suri A, Aoki D, Sugiyama T. Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer. 2021 Mar;32(2):e16	J Gynecol Oncol.
Kazuhiro Takehara , Takashi Matsumoto, Junzo Hamanishi, Kosei Hasegawa, Motoki Matsuura, Kiyonori Miura, Shoji Nagao, Hidekatsu Nakai, Naotake Tanaka, Hideki Tokunaga, Kimio Ushijima, Hidemichi Watari, Yoshihito Yokoyama, Yoichi Kase, Shuui Sumino, Ajit Suri, Hiroaki Itamochi, Nobuhiro Takeshima. Phase 2 single-arm study on the safety of maintenance niraparib in Japanese patients with platinum-sensitive relapsed ovarian cancer. 2021 Mar;32(2):e21	J Gynecol Oncol.
Jotte R, Cappuzzo F, Vynnychenko I, Stroyakovskiy D, Rodríguez-Abreu D, Hussein M, Soo R, Conter HJ, Kozuki T , Huang KC, Graupner V, Sun SW, Hoang T, Jessop H, McClelland M, Ballinger M, Sandler A, Socinski MA. Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous Non-Small-Cell Lung Cancer (IMpower131): Results From a Randomized Phase III Trial. 2020 Aug;15(8):1351-1360.	J Thorac Oncol.
Onda T, Oishi Tanaka Y, Kitai S, Manabe T, Ishikawa M, Hasumi Y, Miyamoto K, Ogawa G, Satoh T, Saito T, Kasamatsu T, Nakanishi, T Takehara K , Okamoto A, Takano T, Yamamoto K, Nagai T, Yaegashi N, Kamura T, Yoshikawa H. Stage III disease of ovarian, tubal and peritoneal cancers can be accurately diagnosed with pre-operative CT. Japan Clinical Oncology Group Study JCOG0602. 2020 Aug;51(2):205-212	Japanese Journal of Clinical Oncology
Ohsumi S , Mukai H, Takahashi M, Hozumi Y, Akabane H, Park Y, Tokunaga E, Takashima T, Watanabe T, Sagara Y, Kaneko T, Ohashi Y. Factors Affecting Enrollment in Randomized Controlled Trials Conducted for Patients With Metastatic Breast Cancer. 2020 Aug 4;50(8):873-881.	Jpn J Clin Oncol.
Kubo T, Watanabe H, Ninomiya K, Kudo K, Minami D, Murakami E, Ochi N, Ninomiya T, Harada D , Yasugi M, Ichihara E, Ohashi K, Rai K, Fujiwara K, Hotta K, Tabata M, Maeda Y, Kiura K. Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients . 2020 Dec 16;50(12):1447-1453	Jpn J Clin Oncol.
Hosokawa S, Ichihara E, Bessho A, Harada D , Inoue K, Shibayama T, Kishino D, Harita S, Ochi N, Oda N, Hara N, Hotta K, Maeda Y, Kiura K. Impact of previous thoracic radiation therapy on the efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer. 2021 Feb 8;51(2):279-286	Jpn J Clin Oncol.
Saka H, Nishio M, Hida T, Nakagawa K, Sakai H, Nogami N , Atagi S, Takahashi T, Horinouchi H, Takenoyama M, Katakami N, Tanaka H, Takeda K, Satouchi M, Isobe H, Maemondo M, Goto K, Hirashima T, Minato K, Yada N, Tamura T. Five-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: pooled analysis of the ONO-4538-05 and ONO-4538-06 studies . 2021 Jan 1;51(1):106-113.	Jpn J Clin Oncol.
Tsuchiya M, Horio Y, Funazaki H, Aogi K , Miyauchi K, Arai Y, Takahashi M. Impact of gender and employment type on job loss among cancer survivors. 2020 Jul 9;50(7):766-771.	Jpn J Clin Oncol.
Yamasaki S, Kada A, Nagai H, Yoshida I , Choi I, Miyata Y, Miyazawa Y, Saito A, Iwasaki H. Rituximab-Mediated Complement-Dependent Cytotoxicity Enhanced by Gemcitabine in Older Patients with Previously Rituximab-Treated Diffuse Large B-Cell Lymphoma: Study Protocol.	Kurume Med J.

Sato J, Satouchi M, Itoh S, Okuma Y, Niho S, Mizugaki H, Murakami H, Fujisaka Y, Kozuki T , Nakamura K, Nagasaka Y, Kawasaki M, Yamada T, Machida R, Kuchiba A, Ohe Y, Yamamoto N. Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial .2020 Jun;21(6):843-850.	Lancet Oncol.
Ohashi K, Ninomiya K, Yoshioka H, Bessho A, Shibayama T, Aoe K, Ishikawa N, Kozuki T , Kawai H, Kuyama S, Miyoshi S, Fujitaka K, Obata H, Tsubata Y, Awaya Y, Inoue M, Inoue K, Horita N, Yanai H, Hotta K, Kiura K. Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysis.2020 Dec;150:83-89.	Lung Cancer.
Zenke Y, Niho S, Umemura S, Ishihara M, Seki N, Nogami N , Hosomi Y, Shimokawa T, Tokito T, Goto Y, Miura Y, Saito H, Hida N, Ikeda S, Tanaka H, Furuya N, Misumi T, Yamanaka T, Ohe Y, Okamoto H. Phase I/II study of carboplatin plus weekly nab-paclitaxel in patients aged 75 years with squamous-cell lung cancer: TORG1322.2020 May 19;146:182-188.	Lung Cancer.
Yoshida I , Saito AM, Tanaka S, Choi I, Hidaka M, Miyata Y, Inoue Y, Yamasaki S, Kagoo T, Iida H, Niimi H, Komeno T, Yoshida C, Tajima F, Yamamoto H, Takase K, Ueno H, Shimomura T, Sakai T, Nakashima Y, Yoshida C, Kubonishi S, Sunami K, Yoshida S, Sakurai A, Kaneko Y, Miyazaki Y, Nagai H. Intravenous itraconazole compared with liposomal amphotericin B as empirical antifungal therapy in patients with neutropenia and persistent fever.2020 Aug;63(8):794-801.	Mycoses.
Nakamura Y, Taniguchi H, Ikeda M, Bando H, Kato K, Morizane C, Esaki T, Komatsu Y, Kawamoto Y, Takahashi N, Ueno M, Kagawa Y, Nishina T , Kato T, Yamamoto Y, Furuse J, Denda T, Kawakami H, Oki E, Nakajima T, Nishida N, Yamaguchi K, Yasui H, Goto M, Matsushashi N, Ohtsubo K, Yamazaki K, Tsuji A, Okamoto W, Tsuchihara K, Yamanaka T, Miki I, Sakamoto Y, Ichiki H, Hata M, Yamashita R, Ohtsu A, Odegaard JI, Yoshino T. Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies .2020 Dec;26(12):1859-1864.	Nat Med.
H. Okuyama; M. Ikeda; T. Okusaka; M. Furukawa; S. Ohkawa; A. Hosokawa; Y. Kojima; H. Hara; G. Murohisa; K. Shioji; A. Asagi ; N. Mizuno; M. Kojima; T. Yamanaka; J. Furuse. A Phase II Trial of Everolimus in Patients with Advanced Pancreatic Neuroendocrine Carcinoma Refractory or Intolerant to Platinum-Containing Chemotherapy (NECTOR Trial).2020 Oct;110(44512):988-993.	Neuroendocrinology
Kai K, Nasu K, Nishida H, Daa T, Shikama A, Shiozaki T, Kurakazu M, Yano M, Imamura Y, Tokunaga H, Tasaki K, Iida Y, Yamada Y, Morisawa H, Nakagawa S, Fujimoto E , Tsuruta T, Matsumoto H, Arakawa A, Nonaka M, Takano H, Ushiwaka T, Mori T, Ito K, Motohashi T, Teramoto N, Yamada T. Correlation of World Health Organization 2010 Classification for Gastroenteropancreatic Neuroendocrine Neoplasms with the Prognosis of Ovarian Neuroendocrine Neoplasms: Kansai Clinical Oncology Group-Protocol Review Committee/Intergroup Study.2021 Feb;111(4):320-329.	Neuroendocrinology.
Kaneyasu T, Mori S, Yamauchi H, Ohsumi S , Ohno S, Aoki D, Baba S, Kawano J, Miki Y, Matsumoto N, Nagasaki M, Yoshida R, Akashi-Tanaka S, Iwase T, Kitagawa D, Masuda K, Hirasawa A, Arai M, Takei J, Ide Y, Gotoh O, Yaguchi N, Nishi M, Kaneko K, Matsuyama Y, Okawa M, Suzuki M, Nezu A, Yokoyama S, Amino S, Inuzuka M, Noda T, Nakamura S. Prevalence of disease-causing genes in Japanese patients with <i>BRCA1/2</i> -wildtype hereditary breast and ovarian cancer syndrome.2020 Jun 12;6:25.	NPJ Breast Cancer.
Eiji Nakata, Shinsuke Sugihara , Yoshifumi Sugawara , Toshiyuki Kozuki , Daijiro Harada , Naoyuki Nogami , Ryuichi Nakahara, Takayuki Furumatsu, Tomonori Tetsunaga, Toshiyuki Kunisada, Toshifumi Ozaki. Early response of bone metastases can predict tumor response in patients with non-small-cell lung cancer with bone metastases in the treatment with nivolumab.2020 Sep;20(3):2977-2986	Oncol Lett
Noguchi M, Fujimoto K, Arai G, Uemura H, Hashine K , Matsumoto H, Fukasawa S, Kohjimoto Y, Nakatsu H, Takenaka A, Fujisawa M, Uemura H, Naito S, Egawa S, Fujimoto H, Hinotsu S, Itoh K. A randomized phase III trial of personalized peptide vaccination for castration-resistant prostate cancer progressing after docetaxel.2021 Jan;45(1):159-168.	Oncol Rep
Hideaki Takahashi, Masafumi Ikeda, Satoshi Shiba, Hiroshi Imaoka, Akiko Todaka, Kazuhiko Shioji, Kei Yane, Yasushi Kojima, Satoshi Kobayashi, Akinori Asagi , Masato Ozaka, Ryoji Takada, Yoshikuni Nagashio, Shigeru Horiguchi, Akiyoshi Kasuga, Eiichiro Suzuki, Takeshi Terashima, Makoto Ueno, Chigusa Morizane, Junji Furuse. Multicenter Retrospective Analysis of Chemotherapy for Advanced Pancreatic Acinar Cell Carcinoma: Potential Efficacy of Platinum- and Irinotecan-Containing Regimens.2021 Jan 1;50(1):77-82.	Pancreas
Ninomiya K, Yokoyama T, Hotta K, Oze I, Katsui K, Hata T, Yoshioka H, Bessho A, Hosokawa S, Kuyama S, Kudo K, Kozuki T , Harada D , Yasugi M, Murakami T, Nakanishi M, Takigawa N, Maeda Y, Kiura K; Okayama Lung Cancer Study Group. A randomized trial of sodium alginate prevention of esophagitis in LA-NSCLC receiving chemoradiotherapy: OLCSG1401.2021 Mar 1. doi: 10.1007/s00520-021-06092-1. Online ahead of print.	Support Care Cancer.
Kikuuchi M , Akezaki Y, Nakata E, Yamashita N, Tominaga R, Kurokawa H, Hamada M, Aogi K, Ohsumi S, Tsuji T, Sugihara S. Risk Factors of Impairment of Shoulder Function After Axillary Dissection for Breast Cancer.2021 Feb;29(2):771-778	Support Care Cancer.

Ohsumi S , Kiyoto S, Takahashi M, Hara F, Takashima S, Aogi K, Matsuda M, Yamamura N, Doi M. Scalp cooling for hair loss prevention in female Japanese breast cancer patients receiving (neo)adjuvant chemotherapy. 2021 Jan;29(1):437-443.	Support Care Cancer.
Nakajima T, Sakamoto T, Hori S , Yamada S, Ikematsu H, Harada K, Chiu HM, Kiriya S, Michida T, Hotta K, Sakamoto N, Abe T, Chino A, Fukuzawa M, Kobayashi N, Fukase K, Matsuda T, Murakami Y, Ishikawa H, Saito Y. Optimal surveillance interval after piecemeal endoscopic mucosal resection for large colorectal neoplasia: a multicenter randomized controlled trial. 2021 Feb 10. doi: 10.1007/s00464-021-08311-6. Online ahead of print.	Surg Endosc.
Yamaguchi T, Hozumi Y, Sagara Y, Takahashi M, Yoneyama K, Fujisawa T, Osumi S , Akabane H, Nishimura R, Mieno MN, Mukai H. The impact of neoadjuvant systemic therapy on breast conservation rates in patients with HER2-positive breast cancer: Surgical results from a phase II randomized controlled trial. 2021 Mar;36:51-55.	Surg Oncol.
Izawa N, Shitara K, Yonesaka K, Yamanaka T, Yoshino T, Sunakawa Y, Masuishi T, Denda T, Yamazaki K, Moriwaki T, Okuda H, Kondoh C, Nishina T , Makiyama A, Baba H, Yamaguchi H, Nakamura M, Hyodo I, Muro K, Nakajima TE. Early Tumor Shrinkage and Depth of Response in the Second-Line Treatment for KRAS exon2 Wild-Type Metastatic Colorectal Cancer: An Exploratory Analysis of the Randomized Phase 2 Trial Comparing Panitumumab and Bevacizumab in Combination with FOLFIRI (WJOG6210G). 2020 Oct;15(5):623-633.	Target Oncol.
Kazuya Nishii, Masaaki Inoue, Hideto Obata, Yutaka Ueda, Toshiyuki Kozuki , Masahiro Yamasaki, Tomonori Moritaka, Yoshikazu Awaya, Keisuke Sugimoto, Kenichi Gemba, Shoichi Kuyama, Hirohisa Ichikawa, Takuo Shibayama, Tetsuya Kubota, Masahiro Kodani, Daizo Kishino, Nobukazu Fujimoto, Nobuhisa Ishikawa, Yukari Tsubata, Tomoya Ishii, Kazunori Fujitaka, Katsuyuki Hotta, Katsuyuki Kiura. Novel prospective umbrella-type lung cancer registry study for clarifying clinical practice patterns: CS-Lung-003 study protocol. 2021 Mar;12(5):725-731	Thorac Cancer
Daijiro Harada , Hideko Isozaki, Toshiyuki Kozuki, Toshihide Yokoyama, Hiroshige Yoshioka, Akihiro Bessho, Shinobu Hosokawa, Ichiro Takata, Nagio Takigawa, Katsuyuki Hotta, Katsuyuki Kiura, Okayama Lung Cancer Study Group. Crizotinib for recurring non-small-cell lung cancer with EML4-ALK fusion genes previously treated with alectinib: A phase II trial. 2021 Mar;12(5):643-649.	Thorac Cancer.
Kozuki T , Nogami N, Hataji O, Tsunozuka Y, Seki N, Harada T, Fujimoto N, Bessho A, Takamura K, Takahashi K, Satouchi M, Kato T, Shukuya T, Yamashita N, Okamoto H, Shinkai T; Thoracic Oncology Research Group. Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab or pemetrexed plus bevacizumab for treatment of elderly (aged 75 years) patients with previously untreated advanced non-squamous non-small cell lung cancer: TORG1323. 2020 Jun;9(3):459-470.	Transl Lung Cancer Res.
Hirama H, Sugimoto M, Miyatake N, Kato T, Venderbos LDF, Remmers S, Shiga K, Yokomizo A, Mitsuzuka K, Matsumoto R, Osawa T, Abe T, Sasaki H, Egawa S, Ninomiya I, Hashine K , Roobol MJ, Kakehi Y. Health-related quality of life in Japanese low-risk prostate cancer patients choosing active surveillance: 3-year follow-up from PRIAS-JAPAN. 2020 Oct 20. doi: 10.1007/s00345-020-03494-4. Online ahead of print.	World J Urol.
秋定直樹, 門田伸也, 岸野毅日人, 青井二郎, 林祐志, 高橋紗央里, 中村匡孝. 中咽頭前壁癌に対する舌正中アプローチと舌弁後方移動術による再建について. 日本気管食道科学会会報2020;72(1):38-46	日本気管食道科学会会報
岸野毅日人, 森照茂, 宮下武憲, 大内陽平, 寒川泰, 福村崇, 高橋幸稔, 三谷知生, 星川広史. 頭頸部扁平上皮癌終末期症例に対する予後予測ツールとしての palliative prognosis index, Glasgow prognostic score の有用性. 日本耳鼻咽喉科学会会報2020;72(1):38-46	日本耳鼻咽喉科学会会報
門田伸也. 【カラー術中写真でよくわかる 達人による頭頸部がん拡大切除】 喉頭・咽頭手術 頸部食道摘出術(喉頭温存), 耳鼻咽喉科・頭頸部外科2020;92(13):1128-1133	耳鼻咽喉科・頭頸部外科
門田伸也. 頭頸部癌治療の機能温存 甲状腺癌手術における喉頭機能温存. 日本気管食道科学会会報2020;71(2):191-193	日本気管食道科学会会報
岸野毅日人, 門田伸也. 【耳鼻咽喉科の問診のポイント-どこまで診断に近づけるか-】 診断精度を上げる問診のポイント 頭頸部腫瘍に対する問診のポイント. ENTONI2020;244:139-144	
岩川明日香, 假谷彰文, 石原久司, 秋定直樹, 藤さやか, 赤木成子, 馬屋原孝恒, 田村麻衣子, 竹内誠, 竹内彩子. 難治性潰瘍性口内炎を契機に判明した急性リンパ性白血病の1例. 岡山赤十字病院医学雑誌2020;31(1):63-66	岡山赤十字病院医学雑誌
中村匡孝, 門田伸也, 岸野毅日人, 青井二郎, 秋定直樹, 林祐志, 高橋紗央里. 甲状腺乳頭癌における外側区域リンパ節転移と遠隔転移の関連についての検討. 頭頸部外科2020;30(3):303-308	頭頸部外科
秋定直樹, 門田伸也, 波呂卓, 岸野毅日人, 青井二郎, 林祐志, 高橋紗央里, 中村匡孝, 上田陽子, 藤崎智明. セツキシマブ併用放射線療法後に発症した後天性血友病. 頭頸部外科2020;30(3):395-400	頭頸部外科
森俊太, 野上尚之. FLAURA最終解析結果. 腫瘍内科2020;25(4):448-456	腫瘍内科
上月稔幸. COVID-19パンデミックにおける肺癌診療 Expert opinion. 肺癌2020;60(4):249-291	肺癌

上月稔幸.肺癌に対する免疫チェックポイント阻害剤の進歩.癌と化学療法2020;47(8):1178-1187	癌と化学療法
日野佳織, 梶原猛史, 仁科智裕, 井上知謙, 吉松萌美, 坂口智紘, 中舎晃男, 西出憲史, 浅木彰則, 長谷部昌, 寺尾孝志, 堀伸一郎, 灘野成人, 濱本泰, 片岡正明, 谷水正人.高齢者食道癌に対する根治的放射線療法.癌と化学療法2020;47(11):1577-1581	癌と化学療法
小林成行, 小島誉也, 落合亮二, 岩田一馬, 大澤真那人, 兼定 弦, 大亀正義, 阿部陽介, 羽藤慎二, 大田耕司, 野崎功雄.腹膜播種による腸閉塞に対する緩和手術成績と予後因子.日本臨床外科学会雑誌2020;81(6):1029-1035	日本臨床外科学会雑誌
落合亮二, 小島誉也, 小林成行, 羽藤慎二, 大田耕司, 野崎功雄.大腸癌膀胱浸潤による膀胱全摘症例に対し新膀胱による尿路変向術を施行した3例.手術2020;74(11):1631-1638	手術
岩田一馬, 小島誉也, 落合亮二, 小林成行, 香川哲也, 御厨美洋, 羽藤慎二, 大田耕司, 寺本典弘, 野崎功雄.粘膜内癌と術前診断された放射線誘導進行直腸癌の1切除例.日本消化器外科学会雑誌2020;54(1):66-72	日本消化器外科学会雑誌
大住省三.遺伝性乳癌卵巣癌 (HBOC) .臨床外科2020;75(8):935-940	臨床外科
青儀健二郎.第4章 医療の質 5.臨床試験 (臨床研究) .乳腺腫瘍学 第3版2020;397-399	乳腺腫瘍学 第3版
富田諒太郎, 新井政介, 井内俊輔, 松村正文, 橋根勝義.回腸利用新膀胱造設術後の患者報告アウトカム.日本泌尿器科学会雑誌2020;111(4):107-113	日本泌尿器科学会雑誌
宮木康成, 竹原和宏, 三宅貴仁.AIによるコルポスコピー診断.産婦人科の実際2020;69(5):475-481	産婦人科の実際
竹原和宏, 横山良仁, 榎本隆之.婦人科がん臨床研究のトレンドを知る 婦人科悪性腫瘍研究機構 (JGOG) .診断と治療社2020;87(6):663-668	診断と治療社
佐藤慎也, 竹原和宏, 紀川純三.婦人科がん臨床研究のトレンドを知る 三海婦人科癌スタディグループ.診断と治療社2020;87(6):705-709	診断と治療社
竹原和宏.マイクロサテライト不安定性と婦人科がん.日本産婦人科医会会報2020;56:16-21	日本産婦人科医会会報
竹原和宏.子宮体がん. 子宮体癌免疫チェックポイント阻害剤.婦人科腫瘍治療アップデート2020:108-110	婦人科腫瘍治療アップデート
竹原和宏.診療に苦慮する婦人科悪性腫瘍 子宮肉腫 子宮平滑筋肉腫の診療の現状.日本産科婦人科学会雑誌2020;72(12):1571	日本産科婦人科学会雑誌
杉原進介, 国定俊之, 尾崎敏文.【肉腫-基礎・臨床の最新知見-】肉腫の外科的治療 その他 術後リハビリテーション.日本臨床2020;78(増5):415-419	日本臨床
菊内 祐人, 明崎 禎輝, 中田 英二, 富永 律子, 黒河 英彰, 濱田 麻紀子, 濱田 和範, 大倉 三洋, 青儀 健二郎, 大住 省三, 杉原 進介.乳がん術後患者におけるリハビリテーション介入の実施による短期間の推移 1症例の検討.保健医療学雑誌2020;11(1):40-47	保健医療学雑誌
富永 律子, 中山 盛皓, 濱田 麻紀子, 杉原 進介, 河村 進.症例から学ぶリンパ浮腫治療 高血圧を伴った下肢リンパ浮腫症例(解説).日本リンパ浮腫治療学会雑誌2020;4(1):91-95	日本リンパ浮腫治療学会雑誌
清野 正普, 杉原 進介, 藤村 亮, 志渡澤 央和, 藤井 洋佑, 塩崎 泰之, 佐藤 亮三, 阿達 啓介.子宮頸癌に対する放射線治療後に発生した骨盤脆弱性骨折のリスク因子の検討.三豊総合病院雑誌2020;41:25-33	三豊総合病院雑誌
宇都宮 遼, 中川 いづみ, 濱田 信.がん専門施設の職員における流行性ウイルス感染症 (麻疹・風疹・水痘・流行性耳下腺炎) の抗体保有状況の検討.日本環境感染学会誌2020;36(2):105-110	日本環境感染学会誌
大池祐子, 宮脇聡子.COVID-19の影響下での院内教育の見直しとマネジメント～確かな知識と技術を継続して学べる環境を目指して～.ナースマネージャー2020;22(9):41-45	ナースマネージャー
武吉 純代, 田邊 富江, 多田 清美.連続特集 がん専門病院におけるコロナ禍でのモチベーション管理.看護実践の科学2020;46(3):24-32	看護実践の科学
寺本 典弘.【術中迅速診断-どこまで答えるべきか?-】術中迅速診断の実際 迅速診断あるある「その迅速診断いるの?」.病理と臨床2020;39(1):62-64	病理と臨床
井口東郎, 高野利実, 三ツ木健二, 山下夏美.消化器がん領域における骨転移診療の標準化に関する研究.共済医報2020;69(2):197-203	共済医報
藤山幹子.アパルタミドによる苔癬型薬疹の2例.日本皮膚科学会雑誌2020;130(7):1653-1657	日本皮膚科学会雑誌
藤山幹子.DIHSの病態におけるヘルペスウイルスの役割.Derma.2020;297:60-66	Derma.

藤山幹子.抗がん薬、免疫チェックポイント阻害薬による薬疹.調剤と情報2020;26(9):1638-1642	調剤と情報
眞田 紗代子, 中岡 啓喜, 藤山 幹子.Hyperkeratosis of nipple and areolaの治療経験.皮膚病診療2020;42(8):686-689	皮膚病診療
宮崎 生子, 平木 舞, 小山 樹里, 藤山 幹子.入院治療を要した多形紅斑型薬疹、播種状紅斑丘疹型薬疹の原因薬剤の傾向分析.日本皮膚免疫アレルギー学会雑誌2020;3(3):403-412	日本皮膚免疫アレルギー学会雑誌
山本 有紀, 清原 祥夫, 仁科 智裕, 藤山 幹子, 山崎 直也, 山本 信之, 川島 眞.EGFR阻害薬・マルチキナーゼ阻害薬に起因する皮膚障害の治療手引き(2020年改訂版) 皮膚科・腫瘍内科有志コンセンサス会議からの提案.Progress in Medicine2020;40(12):1315-1329	Progress in Medicine
藤山幹子.薬疹.今日の小児治療指針 第17版2020:809	今日の小児治療指針 第17版
濱本 泰, 靄岡慎太郎, 西崎統, 牧田憲二, 武田英樹, 真鍋俊治, 望月輝一.再発を繰り返す脳転移への3コース以上の脳定位照射の施行経験.臨床放射線2020;65(10):1135-1142	臨床放射線
吉田 功.「化学療法による血液毒性と感染症対策のポイント」.悪性リンパ腫治療マニュアル 改訂第5版2020:85-89	悪性リンパ腫治療マニュアル 改訂第5版
吉田 功.古典的ホジキンリンパ腫に対する造血幹細胞移植.血液内科2020;81(6):788-793	血液内科
吉田 功.高齢者びまん性大細胞型B細胞リンパ腫 (DLBCL) の治療方針.EBM血液疾患の治療2021-2022 2020:312-318	EBM血液疾患の治療2021-2022